{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:46:12Z","timestamp":1791179172793,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s12094-010-0527-3","type":"journal-article","created":{"date-parts":[[2010,6,15]],"date-time":"2010-06-15T16:00:12Z","timestamp":1276617612000},"page":"401-409","source":"Crossref","is-referenced-by-count":29,"title":["Epigenetic therapy of lymphoma using histone deacetylase inhibitors"],"prefix":"10.1007","volume":"12","author":[{"given":"Maribel","family":"Cotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Cabanillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"Tirado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda V.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,16]]},"reference":[{"key":"527_CR1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"S. Minucci","year":"2006","unstructured":"Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38\u201351","journal-title":"Nat Rev Cancer"},{"key":"527_CR2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.tips.2004.09.004","volume":"25","author":"B. Brueckner","year":"2004","unstructured":"Brueckner B, Lyko F (2004) DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy. Trends Pharmacol Sci 25:551\u2013554","journal-title":"Trends Pharmacol Sci"},{"key":"527_CR3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/38664","volume":"389","author":"M. Grunstein","year":"1997","unstructured":"Grunstein M (1997) Histone acetylation in chromatin structure and transcription. Nature 389:349\u2013352","journal-title":"Nature"},{"key":"527_CR4","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jcb.22185","volume":"107","author":"P.A. Marks","year":"2009","unstructured":"Marks PA, Xu WS (2009) Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107:600\u2013608","journal-title":"J Cell Biochem"},{"key":"527_CR5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/jcb.20532","volume":"96","author":"M. Dokmanovic","year":"2005","unstructured":"Dokmanovic M, Marks PA (2005) Prospects: histone deacetylase inhibitors. J Cell Biochem 96:293\u2013304","journal-title":"J Cell Biochem"},{"key":"527_CR6","first-page":"151","volume":"2","author":"K.B. Glaser","year":"2003","unstructured":"Glaser KB, Staver MJ, Waring JF et al (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2:151\u2013163","journal-title":"Mol Cancer Ther"},{"key":"527_CR7","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"J.G. Herman","year":"2003","unstructured":"Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042\u20132054","journal-title":"N Engl J Med"},{"key":"527_CR8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"A.A. Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503\u2013511","journal-title":"Nature"},{"key":"527_CR9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/00000478-200404000-00005","volume":"28","author":"C.C. Chang","year":"2004","unstructured":"Chang CC, McClintock S, Cleveland RP et al (2004) Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 28:464\u2013470","journal-title":"Am J Surg Pathol"},{"key":"527_CR10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.mcp.2005.09.008","volume":"20","author":"A. Mogal","year":"2006","unstructured":"Mogal A, Abdulkadir SA (2006) Effects of histone deacetylase inhibitor (HDACi) trichostatin-A (TSA) on the expression of housekeeping genes. Mol Cell Probes 20:81\u201386","journal-title":"Mol Cell Probes"},{"key":"527_CR11","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","volume":"358","author":"M. Esteller","year":"2008","unstructured":"Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148\u20131159","journal-title":"N Engl J Med"},{"key":"527_CR12","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/sj.embor.7400456","volume":"6","author":"M. Esteller","year":"2005","unstructured":"Esteller M, Almouzni G (2005) How epigenetics integrates nuclear functions. Workshop on epigenetics and chromatin: transcriptional regulation and beyond. EMBO Rep 6:624\u2013628","journal-title":"EMBO Rep"},{"key":"527_CR13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/ng1531","volume":"37","author":"M.F. Fraga","year":"2005","unstructured":"Fraga MF, Ballestar E, Villar-Garea A et al (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391\u2013400","journal-title":"Nat Genet"},{"key":"527_CR14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3747\/co.v15i5.371","volume":"15","author":"D.R. Walkinshaw","year":"2008","unstructured":"Walkinshaw DR, Yang XJ (2008) Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol 15:237\u2013243","journal-title":"Curr Oncol"},{"key":"527_CR15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000186051","volume":"9","author":"K.H. Lee","year":"2009","unstructured":"Lee KH, Lotterman C, Karikari C et al (2009) Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 9:293\u2013301","journal-title":"Pancreatology"},{"key":"527_CR16","first-page":"3081","volume":"24","author":"M. Bai","year":"2004","unstructured":"Bai M, Skyrlas A, Agnantis NJ et al (2004) Cluster analysis of apoptosis-associated bcl2 family proteins in diffuse large B-cell lymphomas. Relations with the apoptotic index, the proliferation profile and the B-cell differentiation immunophenotypes. Anticancer Res 24:3081\u20133088","journal-title":"Anticancer Res"},{"key":"527_CR17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.humpath.2006.06.017","volume":"38","author":"M. Bai","year":"2007","unstructured":"Bai M, Papoudou-Bai A, Horianopoulos N et al (2007) Expression of bcl2 family proteins and active caspase 3 in classical Hodgkin\u2019s lymphomas. Hum Pathol 38:103\u2013113","journal-title":"Hum Pathol"},{"key":"527_CR18","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1073\/pnas.0500369102","volume":"102","author":"M.J. Peart","year":"2005","unstructured":"Peart MJ, Smyth GK, van Laar RK et al (2005) Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102:3697\u2013702","journal-title":"Proc Natl Acad Sci U S A"},{"key":"527_CR19","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/sj.onc.1203963","volume":"19","author":"L. Huang","year":"2000","unstructured":"Huang L, Sowa Y, Sakai T et al (2000) Activation of the p21WAF1\/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 19:5712\u20135719","journal-title":"Oncogene"},{"key":"527_CR20","first-page":"2891","volume":"63","author":"R. Ju","year":"2003","unstructured":"Ju R, Muller MT (2003) Histone deacetylase inhibitors activate p21(WAF1) expression via ATM. Cancer Res 63:2891\u20132897","journal-title":"Cancer Res"},{"key":"527_CR21","first-page":"61","volume":"8","author":"R.K. Lindemann","year":"2004","unstructured":"Lindemann RK, Johnstone RW (2004) Histone deacetylase inhibitors: promising candidates for chemotherapeutic drugs. Gene Ther Mol Biol 8:61\u201374","journal-title":"Gene Ther Mol Biol"},{"key":"527_CR22","first-page":"369","volume":"11","author":"L. Mullauer","year":"1998","unstructured":"Mullauer L, Mosberger I, Chott A (1998) Fas ligand expression in nodal non-Hodgkin\u2019s lymphoma. Mod Pathol 11:369\u2013375","journal-title":"Mod Pathol"},{"key":"527_CR23","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1074\/jbc.M106699200","volume":"277","author":"S.H. Kwon","year":"2002","unstructured":"Kwon SH, Ahn SH, Kim YK et al (2002) Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas\/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 277:2073\u20132080","journal-title":"J Biol Chem"},{"key":"527_CR24","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00432-008-0522-z","volume":"135","author":"K. Yamanegi","year":"2009","unstructured":"Yamanegi K, Yamane J, Hata M et al (2009) Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death. J Cancer Res Clin Oncol 135:879\u2013889","journal-title":"J Cancer Res Clin Oncol"},{"key":"527_CR25","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1073\/pnas.0702294104","volume":"104","author":"R.K. Lindemann","year":"2007","unstructured":"Lindemann RK, Newbold A, Whitecross KF et al (2007) Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A 104:8071\u20138076","journal-title":"Proc Natl Acad Sci U S A"},{"key":"527_CR26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1476-4598-5-71","volume":"5","author":"J. Chen","year":"2006","unstructured":"Chen J, Ghazawi FM, Bakkar W et al (2006) Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt\/protein kinase B. Mol Cancer 5:71","journal-title":"Mol Cancer"},{"key":"527_CR27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nature03147","volume":"432","author":"R.T. Phan","year":"2004","unstructured":"Phan RT, Dalla-Favera R (2004) The BCL6 protooncogene suppresses p53 expression in germinalcentre B cells. Nature 432:635\u2013639","journal-title":"Nature"},{"key":"527_CR28","doi-asserted-by":"crossref","first-page":"22045","DOI":"10.1074\/jbc.M201736200","volume":"277","author":"C. Lemercier","year":"2002","unstructured":"Lemercier C, Brocard MP, Puvion-Dutilleul F et al (2002) Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J Biol Chem 277:22045\u201322052","journal-title":"J Biol Chem"},{"key":"527_CR29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/ng0993-66","volume":"5","author":"J.P. Kerckaert","year":"1993","unstructured":"Kerckaert JP, Deweindt C, Tilly H et al (1993) LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. Nat Genet 5:66\u201370","journal-title":"Nat Genet"},{"key":"527_CR30","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.1200\/JCO.2005.05.014","volume":"23","author":"O.A. O\u2019Connor","year":"2005","unstructured":"O\u2019Connor OA (2005) Targeting Histones and Proteasomes: New Strategies for the Treatment of Lymphoma. J Clin Oncol 23:6429\u20136436","journal-title":"J Clin Oncol"},{"key":"527_CR31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/MOH.0b013e328302c7df","volume":"15","author":"W. Ci","year":"2008","unstructured":"Ci W, Polo JM, Melnick A (2008) B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma. Curr Opin Hematol 15:381\u2013390","journal-title":"Curr Opin Hematol"},{"key":"527_CR32","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1182\/blood.V83.7.1757.1757","volume":"83","author":"F. Coco Lo","year":"1994","unstructured":"Lo Coco F, Ye BH, Lista F et al (1994) Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin\u2019s lymphoma. Blood 83:1757\u20131759","journal-title":"Blood"},{"key":"527_CR33","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2007-04-087734","volume":"111","author":"B.B. Ding","year":"2008","unstructured":"Ding BB, Yu JJ, Yu RY et al (2008) Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111: 1515\u20131523","journal-title":"Blood"},{"key":"527_CR34","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-07-1595","volume":"13","author":"R.K. Amaravadi","year":"2007","unstructured":"Amaravadi RK, Thompson CB (2007) The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 13:7271\u20137279","journal-title":"Clin Cancer Res"},{"key":"527_CR35","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1172\/JCI28833","volume":"117","author":"R.K. Amaravadi","year":"2007","unstructured":"Amaravadi RK, Yu D, Lum JJ et al (2007) Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 117:326\u2013336","journal-title":"J Clin Invest"},{"key":"527_CR36","first-page":"201","volume":"2","author":"J.S. Carew","year":"2008","unstructured":"Carew JS, Nawrocki ST, Giles FJ et al (2008) Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance. Biologics 2:201\u2013204","journal-title":"Biologics"},{"key":"527_CR37","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.bbrc.2008.03.019","volume":"369","author":"M. Oh","year":"2008","unstructured":"Oh M, Choi IK, Kwon HJ (2008) Inhibition of histone deacetylase1 induces autophagy. Biochem Biophys Res Commun 369:1179\u20131183","journal-title":"Biochem Biophys Res Commun"},{"key":"527_CR38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1124\/mol.109.056309","volume":"76","author":"A.P. Martin","year":"2009","unstructured":"Martin AP, Park MA, Mitchell C et al (2009) BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol Pharmacol 76:327\u2013341","journal-title":"Mol Pharmacol"},{"key":"527_CR39","doi-asserted-by":"crossref","unstructured":"Carew JS, Medina EC, Esquivel JA 2nd et al (2009) Autophagy inhibition enhances vorinostatinduced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med [Epub ahead of print]","DOI":"10.1111\/j.1582-4934.2009.00832.x"},{"key":"527_CR40","first-page":"925","volume":"114","author":"M. Gupta","year":"2009","unstructured":"Gupta M, Stenson M, Lasho T et al (2009) Interplay between histone deacetylases (HDACs) and STAT3: mechanism of activated JAK\/STAT3 oncogenic pathway in ABC (activated B-cell)-type diffuse large B cell lymphoma. ASH Annual Meeting Abstracts 114:925","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"Suppl3","key":"527_CR41","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1080\/10428190310001621588","volume":"44","author":"L. Pasqualucci","year":"2003","unstructured":"Pasqualucci L, Bereschenko O, Niu H et al (2003) Molecular pathogenesis of non-Hodgkin\u2019s lymphoma: the role of Bcl-6. Leuk Lymphoma 44(Suppl 3):S5\u2013S12","journal-title":"Leuk Lymphoma"},{"key":"527_CR42","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1158\/0008-5472.CAN-03-0799","volume":"64","author":"N. Gurvich","year":"2004","unstructured":"Gurvich N, Tsygankova OM, Meinkoth JL et al (2004) Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64:1079\u20131086","journal-title":"Cancer Res"},{"key":"527_CR43","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0145-2126(01)00151-5","volume":"26","author":"R. Kawagoe","year":"2002","unstructured":"Kawagoe R, Kawagoe H, Sano K (2002) Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res 26:495\u2013502","journal-title":"Leuk Res"},{"key":"527_CR44","first-page":"633","volume":"31","author":"A. Fedier","year":"2007","unstructured":"Fedier A, Dedes KJ, Imesch P et al (2007) The histone deacetylase inhibitors suberoylanilide hydroxamic (vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Int J Oncol 31:633\u2013641","journal-title":"Int J Oncol"},{"key":"527_CR45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1179\/joc.2006.18.4.415","volume":"18","author":"I. Friedmann","year":"2006","unstructured":"Friedmann I, Atmaca A, Chow KU et al (2006) Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. J Chemother 18:415\u2013420","journal-title":"J Chemother"},{"key":"527_CR46","first-page":"293","volume":"22","author":"J. Jones","year":"2008","unstructured":"Jones J, Bentas W, Blaheta RA et al (2008) Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid. Int J Mol Med 22:293\u2013299","journal-title":"Int J Mol Med"},{"key":"527_CR47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jss.2008.03.008","volume":"148","author":"C.S. Platta","year":"2008","unstructured":"Platta CS, Greenblatt DY, Kunnimalaiyaan M et al (2008) Valproic acid induces Notch1 signaling in small cell lung cancer cells. J Surg Res 148:31\u201337","journal-title":"J Surg Res"},{"key":"527_CR48","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1158\/1535-7163.MCT-08-1076","volume":"8","author":"M.S. Kortenhorst","year":"2009","unstructured":"Kortenhorst MS, Isharwal S, van Diest PJ et al (2009) Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo. Mol Cancer Ther 8:802\u2013808","journal-title":"Mol Cancer Ther"},{"key":"527_CR49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1124\/jpet.106.106658","volume":"319","author":"C.L. Chen","year":"2006","unstructured":"Chen CL, Sung J, Cohen M et al (2006) Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. J Pharmacol Exp Ther 319:533\u2013542","journal-title":"J Pharmacol Exp Ther"},{"key":"527_CR50","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1593\/tlo.08136","volume":"1","author":"S. Sharma","year":"2008","unstructured":"Sharma S, Symanowski J, Wong B et al (2008) A phase II clinical trial of oral valproic acid in patients with castration-resistant prostate cancers using an intensive biomarker sampling strategy. Transl Oncol 1:141\u2013147","journal-title":"Transl Oncol"},{"key":"527_CR51","first-page":"1720","volume":"114","author":"S. Zhu","year":"2009","unstructured":"Zhu S, Denman CJ, Lee DA (2009) Valproic acid selectively inhibits STAT3 phosphorylation. ASH Annual Meeting Abstracts 114:1720","journal-title":"ASH Annual Meeting Abstracts"},{"key":"527_CR52","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","volume":"12","author":"W.S. Velasquez","year":"1994","unstructured":"Velasquez WS, McLaughlin P, Tucker S et al (1994) ESHAP-An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4 year follow-up study. J Clin Oncol 12:1169\u20131176","journal-title":"J Clin Oncol"},{"key":"527_CR53","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","volume":"103","author":"T. Kewalramani","year":"2004","unstructured":"Kewalramani T, Zelenetz AD, Nimer SD et al (2004) Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103:3684\u20133688","journal-title":"Blood"},{"key":"527_CR54","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1080\/10428190701344907","volume":"48","author":"J. Zain","year":"2007","unstructured":"Zain J, Rotter A, Weiss L et al (2007) Valproic acid monotherapy leads to CR in a patient with refractory diffuse large B cell lymphoma. Leuk Lymphoma 48:1216\u20131218","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"527_CR55","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/leu.2009.176","volume":"23","author":"B. Stamatopoulos","year":"2009","unstructured":"Stamatopoulos B, Meuleman N, De Bruyn C et al (2009) Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia 23(12):2281\u20132289","journal-title":"Leukemia"},{"key":"527_CR56","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2119\/2007-00084.Bokelmann","volume":"14","author":"I. Bokelmann","year":"2008","unstructured":"Bokelmann I, Mahlknecht U (2008) Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between proand antiapoptotic proteins. Mol Med 14:20\u201327","journal-title":"Mol Med"},{"key":"527_CR57","unstructured":"P. Ganesan VR, R. Kumar (2009) A phase II pilot study of valproic acid in relapsed\/refractory chronic lymphocytic leukemia. ASCO Meeting Abstract 7081"},{"key":"527_CR58","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1358\/dot.2007.43.9.1112980","volume":"43","author":"M. Duvic","year":"2007","unstructured":"Duvic M, Vu J (2007) Vorinostat in cutaneous T-cell lymphoma. Drugs Today (Barc) 43:585\u2013599","journal-title":"Drugs Today (Barc)"},{"key":"527_CR59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","volume":"109","author":"M. Duvic","year":"2007","unstructured":"Duvic M, Talpur R, Ni X et al (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31\u201339","journal-title":"Blood"},{"key":"527_CR60","first-page":"5213","volume":"112","author":"A. Mazumder","year":"2008","unstructured":"Mazumder A, Vesole DH, Jagannath S (2008) Treatment of multiple myeloma with vorinostat in combination with bortezomib: a case series. ASH Annual Meeting Abstracts 112:5213","journal-title":"ASH Annual Meeting Abstracts"},{"key":"527_CR61","first-page":"5084","volume":"112","author":"G. Garcia-Manero","year":"2008","unstructured":"Garcia-Manero G, Silverman LB, Gojo I et al (2008) A randomized phase IIa study of vorinostat in patients with low or intermediate-1 risk myelodysplastic syndromes: preliminary results. ASH Annual Meeting Abstracts 112:5084","journal-title":"ASH Annual Meeting Abstracts"},{"key":"527_CR62","unstructured":"Kirschbaum M, Popplewell L, Auayporn P et al (2008) A phase 2 study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed or refractory indolent non-Hodgkin\u2019s lymphoma. A California Cancer Consortium study. ASH Annual Meeting Abstract 1564"},{"key":"527_CR63","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/annonc\/mdn031","volume":"19","author":"M. Crump","year":"2008","unstructured":"Crump M, Coiffier B, Jacobsen ED et al (2008) Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 19:964\u2013969","journal-title":"Ann Oncol"},{"issue":"1","key":"527_CR64","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1349-7006.2009.01360.x","volume":"101","author":"T. Watanabe","year":"2009","unstructured":"Watanabe T, Kato H, Kobayashi Y et al (2009) Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 101(1):196\u2013200","journal-title":"Cancer Sci"},{"key":"527_CR65","first-page":"1587","volume":"112","author":"J.L. Cultrera","year":"2008","unstructured":"Cultrera JL, Rosenberg L, McConkey DJ et al (2008) The Histone Deacetylase Inhibitor Vorinostat Induces Apoptosis in T-Cell Lymphoma Cell Lines and Synergizes with Bortezomib. ASH Annual Meeting Abstracts 112:1587","journal-title":"ASH Annual Meeting Abstracts"},{"key":"527_CR66","first-page":"3711","volume":"112","author":"D.M. Weber","year":"2008","unstructured":"Weber DM, Jagannath S, Sobecks R et al (2008) Combination of vorinostat plus bortezomib for the treatment of patients with multiple myeloma who have previously received bortezomib. ASH Annual Meeting Abstracts 112:3711","journal-title":"ASH Annual Meeting Abstracts"},{"key":"527_CR67","first-page":"1568","volume":"112","author":"S. Bates","year":"2008","unstructured":"Bates S, Piekarz R, Wright J et al (2008) Final clinical results of a phase 2 NCI multicenter study of romidepsin in recurrent cutaneous T-cell lymphoma (molecular analyses included). ASH Annual Meeting Abstracts 112:1568","journal-title":"ASH Annual Meeting Abstracts"},{"key":"527_CR68","first-page":"445","volume":"8546","author":"M. Demierre","year":"2009","unstructured":"Demierre M, Whittaker, S, Kim, Y et al (2009) Pooled analyses of two international, multicenter clinical studies of romidepsin in 167 patients with cutaneous T-cell lymphoma. Asco Annual Meeting. Abstract 8546:445","journal-title":"Asco Annual Meeting. Abstract"},{"key":"527_CR69","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1358\/dof.2007.032.04.1094476","volume":"32","author":"P. Revill","year":"2007","unstructured":"Revill P, Mealy N, Serradell N et al (2007) Panobinostat. Drugs Future 32:315","journal-title":"Drugs Future"},{"issue":"1","key":"527_CR70","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2141.2009.07837.x","volume":"147","author":"M. Dickinson","year":"2009","unstructured":"Dickinson M, Ritchie D, Deangelo DJ et al (2009) Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol 147(1):97\u2013101","journal-title":"Br J Haematol"},{"key":"527_CR71","doi-asserted-by":"crossref","unstructured":"Rao R, Ficus WC, Yang Y et al (2009) Targeting autophagy induced by pan-HDAC inhibitor panobinostat and promoted by acetylated hsp70: A novel therapy for breast cancer. Mol Cancer Ther 8 (Meeting Abstract Supplement): doi: 10.1158\/1535-7163.TARG-09-B21","DOI":"10.1158\/1535-7163.TARG-09-B21"},{"key":"527_CR72","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1535-7163.MCT-07-2026","volume":"7","author":"M. Fournel","year":"2008","unstructured":"Fournel M, Bonfils C, Hou Y et al (2008) MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7:759\u2013768","journal-title":"Mol Cancer Ther"},{"key":"527_CR73","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2007-10-115873","volume":"112","author":"G. Garcia-Manero","year":"2008","unstructured":"Garcia-Manero G, Assouline S, Cortes J et al (2008) Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112:981\u2013989","journal-title":"Blood"},{"key":"527_CR74","first-page":"2566","volume":"110","author":"A. Younes","year":"2007","unstructured":"Younes A, Pro B, Fanale M et al (2007) Isotypeselective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin lymphoma (HL). ASH Annual Meeting Abstracts 110:2566","journal-title":"ASH Annual Meeting Abstracts"},{"key":"527_CR75","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1158\/1078-0432.CCR-07-1461","volume":"14","author":"L. Gore","year":"2008","unstructured":"Gore L, Rothenberg ML, O\u2019Bryant CL et al (2008) A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 14:4517\u20134525","journal-title":"Clin Cancer Res"},{"key":"527_CR76","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1745-7254.2005.00081.x","volume":"26","author":"H.L. Liu","year":"2005","unstructured":"Liu HL, Chen Y, Cui GH et al (2005) Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation. Acta Pharmacol Sin 26:603\u2013609","journal-title":"Acta Pharmacol Sin"},{"key":"527_CR77","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10059-009-0036-9","volume":"27","author":"Z.X. Li","year":"2009","unstructured":"Li ZX, Ouyang KQ, Jiang X et al (2009) Curcumin induces apoptosis and inhibits growth of human Burkitt\u2019s lymphoma in xenograft mouse model. Mol Cells 27:283\u2013289","journal-title":"Mol Cells"},{"key":"527_CR78","first-page":"2895","volume":"21","author":"A.L. Cheng","year":"2001","unstructured":"Cheng AL, Hsu CH, Lin JK et al (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21:2895\u20132900","journal-title":"Anticancer Res"},{"key":"527_CR79","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ijc.23477","volume":"123","author":"G.G. Mackenzie","year":"2008","unstructured":"Mackenzie GG, Queisser N, Wolfson ML et al (2008) Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-kappaB and STAT3 pathways in Hodgkin\u2019s lymphoma cells. Int J Cancer 123:56\u201365","journal-title":"Int J Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-010-0527-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-010-0527-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-010-0527-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T16:05:42Z","timestamp":1685635542000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-010-0527-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":79,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["527"],"URL":"https:\/\/doi.org\/10.1007\/s12094-010-0527-3","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}